drugset / Trial / NCT03965845
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.
Timeline
- Start
- 2019-06-25
- Primary completion
- 2021-09-24
- Completion
- 2021-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 75 mg | Oral |
| Subject | Palbociclib | Small molecule | 100 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Telaglenestat | Unknown | 600 mg | Oral |
| Subject | Telaglenestat | Unknown | 800 mg | Oral |